鼻至大脑输送系统的进步为有效的阿尔茨海默氏症疾病管理提供了帮助
Alka Sahu1, Khileshwari2, Kavita Patle2
1Department of Pharmacy, Rungta Institute of Pharmaceutical Education and Research, Bhilai, C.G., 490024, India.
Current Alzheimer research
|January 27, 2026
概括
鼻至大脑输送提供了一种非侵入性方法,通过绕过血脑屏障来治疗神经退行性疾病. 这种方法提高了药物的生物可用性和患者的遵从性,尽管广泛临床使用仍然存在挑战.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 包括阿尔茨海默氏症在内的神经退行性疾病涉及逐渐恶化的神经元和共同的机制,如蛋白质聚合和神经炎症.
- 目前的治疗方法面临的局限性是由于血脑屏障的穿透性差以及系统性副作用.
- 鼻至脑 (N2B) 输送系统为中枢神经系统疾病提供了一种新的治疗策略.
研究的目的:
- 审查鼻至脑 (N2B) 输送系统在治疗神经退行性疾病方面的潜力.
- 突出N2B交付的优势,包括非侵入性和直接的CNS准.
- 讨论N2B药物输送系统的挑战和未来方向.
主要方法:
- 对N2B输送系统和它们在神经退行性疾病中的应用现有文献的审查.
- 药物输送载体的分析,如脂质纳米载体,纳米颗粒,树状体和纳米凝,用于N2B应用.
- 检查影响药物运输的因素以及诸如酶降解和粘膜清除等挑战.
主要成果:
- N2B输送利用嗅觉和三角体通道直接运送药物到中枢神经系统,绕过血脑屏障.
- 纳米载体技术增强药物稳定性,向性和受控释放,以优化N2B输送.
- 临床前和临床研究表明有效性,但监管和可扩展性问题仍然存在.
结论:
- 对神经退行性疾病而言,N2B 交付是一种有前途的非侵入性策略,可改善生物可用性和患者遵守性.
- 克服酶降解和粘膜清除等挑战对于N2B系统优化至关重要.
- 跨学科的研究,利用人工智能和个性化医学,对于实现N2B在神经退行性疾病中提供N2B的全部潜力至关重要.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...